Ascendis Pharma (ASND) Q3 2024: Skytrofa Volume Up 60% as YorvaPath U.S. Launch Nears

November 14, 2024 | By EarningsIQ Research

Ascendis Pharma’s rare endocrine portfolio delivered strong clinical and commercial momentum, with Skytrofa’s U.S. adoption accelerating and YorvaPath’s launch infrastructure scaling for January. Management’s strategy to capture market share in growth disorders and hypoparathyroidism is supported by robust clinical data, pipeline progress, and capital from a new Novo Nordisk partnership. Execution on label expansion, international rollout, and operational leverage will determine the long-term blockbuster trajectory.

Summary

• Market Share Expansion: Skytrofa’s once-weekly dosing and payer access are driving rapid U.S. adoption.
• Launch Readiness: YorvaPath’s U.S. launch leverages a scaled sales force and guideline alignment to target a concentrated physician base.
• Pipeline Leverage: Strategic focus on label expansion and Novo Nordisk collaboration positions Ascendis for sustained growth and operational scale.

Business Overview

Ascendis Pharma develops and commercializes long-acting, clinically differentiated therapies for rare endocrine diseases, leveraging its proprietary TransCon technology platform. The core revenue drivers are Skytrofa, a once-weekly growth hormone for pediatric deficiency, and YorvaPath, a replacement therapy for adult hypoparathyroidism. Additional pipeline assets include TransCon-CNP for achondroplasia and a new obesity/metabolic program partnered with Novo Nordisk. The company monetizes through product sales, milestone payments, and royalties.

Performance Analysis

Skytrofa, Ascendis’s flagship once-weekly growth hormone, saw U.S. demand volume rise over 60% year-over-year, reflecting both new patient starts and switches from daily regimens. However, reported revenue growth lagged due to higher sales deductions from expanded payer access, channel inventory timing, and accrual adjustments. Despite these headwinds, underlying realized pricing remains stable, and management expects sequential revenue improvement in Q4 as prescription trends remain strong and additional shipping days support topline growth.

YorvaPath, the first FDA-approved therapy for adult hypoparathyroidism, posted robust ex-U.S. uptake, particularly in Germany and Austria, with over 600 patients on commercial therapy. The U.S. launch infrastructure is in place, with a field force triple the size of Skytrofa’s and a focused strategy targeting the estimated 1,200 endocrinologists managing the majority of eligible patients. Pipeline progress continued, with pivotal data for TransCon-CNP in achondroplasia and plans to submit for regulatory approval in early 2025. The Novo Nordisk partnership provides upfront capital, milestones, and royalties, enabling further investment in global launches and label expansion.

• Skytrofa Volume Growth: U.S. treated patient volume more than doubled year-to-date, even as revenue was offset by payer dynamics and inventory adjustments.
• YorvaPath Commercial Ramp: Ex-U.S. sales grew over 60%, with U.S. launch targeting four key patient segments and leveraging strong clinical guidelines alignment.
• Operating Leverage: R&D expenses fell 34% as key programs advanced, while SG&A rose modestly to support new launches; total operating expenses declined 18% year-over-year.

Cash and liquidity are robust, with €626 million at quarter-end, not including the $100 million Novo Nordisk upfront. Management remains committed to reaching operating cash flow break-even by end-2025.

Executive Commentary

Strategic Positioning

1. Skytrofa’s Platform Leadership in Growth Disorders

Skytrofa’s once-weekly dosing, superior adherence, and high-value positioning underpin its rapid market share gains, especially as daily growth hormone competitors exit the U.S. market. Management is executing on label expansion into adult growth hormone deficiency and pursuing basket trials in additional pediatric and genetic indications, aiming to broaden the addressable market well beyond current pediatric use. Maintaining premium net value per patient—approximately three times daily regimens—remains central to the commercial strategy.

2. YorvaPath U.S. Launch and Market Consolidation

YorvaPath’s launch strategy leverages a concentrated endocrinologist prescriber base, robust clinical guidelines alignment, and absence of direct competition, following Takeda’s NatPAR withdrawal. The company’s expanded field force and patient support infrastructure are designed to maximize initial uptake from both PTH-experienced and treatment-naive patients. The product’s unique true replacement therapy profile and 24/7 physiological coverage are expected to drive rapid conversion and strong retention.

3. Pipeline and Platform Expansion

TransCon-CNP’s pivotal data in achondroplasia positions Ascendis to extend its leadership in growth disorders, with regulatory filings planned for early 2025. The company is also advancing combination trials and basket studies to unlock additional indications. The Novo Nordisk partnership validates the platform’s scalability into high-volume metabolic diseases, with a once-monthly GLP-1 program targeting the rapidly expanding obesity and diabetes markets, and supports future royalty and milestone streams.

4. Operational Discipline and Capital Allocation

Operating expense control and disciplined capital deployment enable simultaneous investment in commercial launches, pipeline advancement, and lifecycle management, while maintaining a strong balance sheet. The company’s cash position and incoming partnership capital provide flexibility to pursue global expansion and operational scale without near-term dilution.

Key Considerations

Ascendis’s Q3 demonstrates a rare combination of clinical execution, commercial momentum, and strategic capital deployment, but the pace of revenue realization and market conversion remain key watchpoints as the company scales multiple launches.

Key Considerations:

• Market Conversion Dynamics: Rapid Skytrofa adoption as daily growth hormone competitors exit, but revenue realization is sensitive to payer access timing and sales deduction accruals.
• U.S. YorvaPath Launch Execution: Success depends on operational readiness, prescriber engagement, and seamless patient transitions from legacy therapies.
• Label Expansion Leverage: Timely regulatory approvals for adult GHD and achondroplasia are critical for full market penetration and long-term growth.
• Pipeline Monetization: Novo Nordisk partnership provides non-dilutive capital and validates platform, but timelines for royalty revenue and additional product launches remain uncertain.

Risks

Revenue visibility remains partially clouded by payer mix, sales deduction timing, and inventory dynamics, as seen in recent Skytrofa revenue adjustments. YorvaPath’s U.S. launch faces execution risk, including potential delays in patient onboarding and reimbursement, as well as competitive pipeline entrants. Pipeline milestones are subject to regulatory timing and data risk, while international expansion depends on country-specific pricing and reimbursement negotiations. Investors should also monitor macro impacts on healthcare utilization and specialty drug budgets.

Forward Outlook

For Q4 2024, Ascendis guided to:

• Sequential Skytrofa revenue growth, supported by stable pricing, increased demand, and additional shipping days
• Full-year Skytrofa revenue (excluding prior period deductions) of €200–220 million

For full-year 2024, management maintained guidance:

• Total operating expenses (SG&A and R&D) of approximately €600 million, inclusive of YorvaPath U.S. launch investment

Management highlighted several factors that will shape near-term results:

• Initial YorvaPath U.S. uptake across four patient segments
• Progress on regulatory filings and basket trials for label expansion

Takeaways

Ascendis enters 2025 with commercial momentum, a robust balance sheet, and a clear path to operating cash flow break-even.

• Commercial Execution: Skytrofa’s differentiated profile is driving rapid share gains, but revenue realization will remain sensitive to payer and channel dynamics as market access broadens.
• Launch Scale-Up: YorvaPath’s U.S. launch is backed by a scaled field force and strong clinical positioning, but execution on patient conversion and reimbursement will be the key determinant of near-term growth.
• Future Levers: Watch for regulatory milestones in adult GHD and achondroplasia, further international launches, and the initial impact of the Novo Nordisk partnership on platform monetization.

Conclusion

Ascendis Pharma’s Q3 2024 results highlight the company’s ability to translate clinical innovation into commercial momentum across rare endocrine diseases. Sustained execution on label expansion, launch readiness, and operational leverage will be critical to realizing the full blockbuster potential of its pipeline and platform.

Industry Read-Through

Ascendis’s rapid adoption of once-weekly growth hormone therapy and its aggressive U.S. launch of YorvaPath signal accelerating market preference for long-acting, high-value rare disease therapies. The ongoing exit of daily growth hormone competitors underscores consolidation pressures and the need for differentiated clinical profiles in specialty pharma. Partnerships with large-cap pharma for platform technologies, as seen with Novo Nordisk, are likely to become more common as biotechs seek non-dilutive capital and access to global commercialization infrastructure. For the rare disease and metabolic disorder sectors, operational discipline and payer strategy will remain gating factors for value realization.

ASND Healthcare Biotechnology Rare Disease Endocrinology Skytrofa YorvaPath Pipeline